Prospect: information for the patient
Fotivda 890microgram hard capsules
Fotivda 1340microgram hard capsules
tivozanib
Read this prospect carefully before starting to take this medication, as it contains important information for you.
1.What is Fotivda and for what it is used
2.What you need to know before starting to take Fotivda
3.How to take Fotivda
4.Possible adverse effects
5.Storage of Fotivda
6.Contents of the package and additional information
The active ingredient of Fotivda is tivozanib, which is a protein kinase inhibitor. Tivozanib reduces blood supply to the cancer, thereby slowing the growth and spread of cancer cells. It acts by blocking the action of a protein called vascular endothelial growth factor (VEGF). The blockade of VEGF action prevents the formation of new blood vessels.
Fotivda is used to treat adults with advanced kidney cancer. It is used when other treatments such as interferon-alpha or interleukin-2 have not been used yet or have not been effective in stopping their disease.
Do not take Fotivda:
Warnings and precautions
Consult your doctor, pharmacist or nurse before starting to take Fotivda:
Fotivda may increase your blood pressure. Your doctor will monitor your blood pressure periodically and, if it is too high, may give you a medicine to reduce it or decide to reduce your dose of Fotivda. However, if your blood pressure remains too high, your doctor may decide to interrupt or stop treatment with Fotivda. If you are already taking a medicine to treat high blood pressure and your doctor reduces your dose of Fotivda or interrupts or stops treatment, you will be monitored periodically for low blood pressure.
Treatment with Fotivda may increase the risk of developing a blood clot (thrombus) in your blood vessels that could break loose and block another blood vessel.
Inform your doctor if you have ever had any of the following problems:
Your doctor will monitor the signs and symptoms of heart failure while you are receiving your medicine. If necessary, your doctor may reduce your dose of Fotivda or interrupt or stop treatment with Fotivda.
Your doctor will monitor your liver function periodically before and during treatment with Fotivda (e.g., with blood tests) and, if necessary, may have to reduce the frequency with which you take Fotivda.
Consult your doctor, pharmacist or nurse while taking Fotivda:
Your doctor will monitor you periodically for these symptoms during your treatment with Fotivda.
Children and adolescents
Do notadminister Fotivda to children and adolescents under 18 years of age. This medicine has not been studied in children and adolescents.
Other medicines and Fotivda
Inform your doctor or pharmacist if you are taking, have taken recently or may need to take any other medicine. This includes herbal medicines and other medicines that you have bought without a prescription.
Fotivda may work less well when taken with some medicines. Inform your doctor if you are taking any of the following medicines; your doctor may decide to change your medication:
Pregnancy, breastfeeding and fertility
Driving and operating machines
Fotivda may have side effects that may affect your ability to drive or operate machines. Do not drive or operate machines if you feel weak, tired or dizzy. See also section 4 "Possible side effects".
Fotivda contains tartrazine (E102)
The printing ink used in the 890 microgram Fotivda capsule contains tartrazine (E102), which may cause allergic reactions.
Follow exactly the administration instructions of this medication as indicated by your doctor. In case of doubt, consult your doctor or pharmacist again.
Recommended dose
The recommended dose is one capsule ofFotivda 1340micrograms, taken once a day for 21days (3weeks), followed by a 7-day period(1 week) when no capsules are taken.
This regimen is repeated in cycles of 4 weeks.
Your doctor will check on you periodically and will normally continue taking Fotivda as long as it works and you do not experience unacceptable side effects.
Reduced dose
If you experience severe side effects, your doctor may decide to interrupt treatment with Fotivda and/or reduce the dose to:
One capsule ofFotivda 890micrograms, taken once a day for 21days (3weeks), followed by a 7-day period (1 week) without taking capsules.
This regimen is repeated in cycles of 4 weeks.
Liver problems
If you haveliver problems, your doctor may reduce the frequency with which your dose is taken to alternate days (this is, one capsule of 1340micrograms on alternate days).
Use of Fotivda with food and drinks
Fotivda should be taken with a glass of water and may be taken with or without food. Swallow the capsule whole. Do not chew, dissolve, or break the capsule before swallowing.
If you take more Fotivda than you should
Inform your doctor immediately if you have taken more than the prescribed dose of 1 capsule per day.
Taking too much Fotivda may make side effects more likely or more intense, especially high blood pressure. Getimmediate medical helpif you experience confusion, changes in your mental state, or headaches. These are all symptoms of high blood pressure.
If you forget to take Fotivda
If you have forgotten to take a capsule,do nottake a capsule to make up for it. Continue taking the next dose at the scheduled time.
Do nottake a double dose to make up for a missed capsule.
If you vomit after taking Fotivda,do nottake a capsule to make up for it. Continue taking the next dose at the scheduled time.
If you interrupt treatment with Fotivda
Do not stop taking this medication unless your doctor tells you to. If you stop taking the capsules, your condition may worsen.
If you have any other questions about the use of this medication, ask your doctor, pharmacist, or nurse.
Like all medicines, this medicine can cause side effects, although not everyone will experience them.
Severe side effects
Hypertensionis the most severe and very frequent side effect (also see section 2“Warnings and precautions”).
Inform your doctor immediatelyif you think you havehigh blood pressure.Symptoms include severe headaches, blurred vision, shortness of breath, changes in your mental state, such as feeling anxious, confused, or disoriented.
Your doctor will check your blood pressure periodically during treatment with Fotivda. If you develop high blood pressure, your doctor may prescribe a medication to treat hypertension, reduce your dose of Fotivda, or stop treatment with Fotivda.
Other side effects
Very common(may affect more than 1 in 10 people)
Common(may affect up to 1 in 10 people)
Rare(may affect up to 1 in 1,000 people)
Unknown frequency(cannot be estimated from available data)
Reporting side effects
If you experience side effects, consult your doctor, pharmacist, or nurse, even if they are side effects that do not appear in this leaflet.You can also report them directly through thenational notification system included in theAppendixV. By reporting side effects, you can contribute to providing more information on the safety of this medicine.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date that appears on the box and the bottle after CAD. The expiration date is the last day of the month indicated.
Keep the bottle perfectly closed to protect it from moisture.
Medicines should not be thrown down the drains or in the trash. Ask your pharmacist how to dispose of the containers and medications that you no longer need. In this way, you will help protect the environment.
Content of Fotivda
Fotivda 890hard capsules
The active ingredient is tivozanib. Each hard capsule contains tivozanib hydrochloride monohydrate equivalent to 890micrograms of tivozanib.
The other components are:
Fotivda 1340micrograms hard capsules
The active ingredient is tivozanib. Each capsule contains tivozanib hydrochloride monohydrate equivalent to 1340micrograms of tivozanib.
The other components are:
Appearance of the product and contents of the pack
Fotivda 890 micrograms hard capsules have a dark blue opaque cap and a bright yellow opaque body, with “TIVZ” printed in yellow ink on the cap and “LD” on the body in dark blue ink.
Fotivda 1340 micrograms hard capsules have a bright yellow opaque cap and body, with “TIVZ” printed in dark blue ink on the cap and “SD” on the body in dark blue ink.
Fotivda 890micrograms and Fotivda 1340micrograms are available in HDPE bottles with child-resistant closures containing 21capsules.
Marketing authorisation holder
Recordati Netherlands B.V.Beechavenue 54,
1119PW Schiphol-Rijk
Netherlands
Manufacturer
ALMAC PHARMA SERVICES (IRELAND) LIMITED
Finnabair Industrial Estate
Dundalk
Co. Louth
A91 P9KD
Ireland
Last update of this leaflet: 07/2023
The detailed information on this medicine is available on the website of the European Medicines Agency:http://www.ema.europa.eu.
Have questions about this medication or your symptoms? Connect with a licensed doctor for guidance and personalized care.